JHP Pharmaceuticals Announces Chief Executive Officer Succession
PARSIPPANY, NJ June 24, 2011 --
JHP Pharmaceuticals (“JHP”) announced today that
Stuart Hinchen would succeed Peter Jenkins as
Chief Executive Officer of the company effective
July 1, 2011. Stuart Hinchen has acted as JHP’s
President and Chief Operating Officer since the
formation of the company in 2007.
Peter Jenkins commented: “Over the past four
years we have established JHP on a secure
financial and operational basis with growing
revenues and strong profitability as well as put
in place an assured platform for growth in both
our marketed products and contract manufacturing
business. In particular, over the past twelve
months, we have established a rapidly growing
pipeline of generic injectable products using
both out-sourced development resources and an
internal development group based at our Michigan
manufacturing facility. The secure position the
business is in provides me with the opportunity
to step back from day to day activities knowing
that the full time leadership of the business is
in excellent hands. I will remain fully invested
and also involved as a consultant with the
business through supporting Stuart with the
development activities.”
Stuart Hinchen commented: “JHP has a wonderful
opportunity over the coming years to actively
redefine the generic injectable competitive
landscape in the USA. Peter remains a valued
architect of our business development efforts
and how we progress the company through future
growth.”
About JHP Pharmaceuticals, LLC
JHP, headquartered in New Jersey, is a specialty
pharmaceutical company which develops,
manufactures and sells pharmaceutical products,
primarily aseptic injectable products into the
hospital segment, and provides contract
manufacturing of sterile products for
pharmaceutical companies. JHP is a private
company wholly owned by JHP Holdings, LLC whose
equity owners are Morgan Stanley Principal
Investments, Peter Jenkins and Stuart Hinchen.
Additional Press Releases
|
02/29/12 |
|
JHP Pharmaceuticals Adds Second Product
To Multi-Year Contract Manufacturing Agreement |
 |
|
Webpage
|
PDF Format |
|
|
|
|
07/25/11 |
|
JHP Pharmaceuticals to Produce Clinical Batches of Innovative Cardiac Drug |
|
|
|
Webpage
|
PDF Format |
|
|
|
|
07/06/11 |
|
JHP Pharmaceuticals Enters Agreement To Produce Life-Saving Drug |
|
|
|
Webpage
|
PDF Format |
|
|
|
|
07/05/11 |
|
JHP Pharmaceuticals Launches New Multipack Presentations of Adrenalin®,
Coly-Mycin® M and Pitocin® |
|
|
|
Webpage
|
PDF Format |
|
|
|
|
06/24/11 |
|
JHP Pharmaceuticals Announces Chief
Executive Officer Succession |
|
|
|
Webpage
|
PDF Format |
|
|
|
|
03/28/11 |
|
JHP Pharmaceuticals Announces Multi-Year
Contract Manufacturing Agreement |
|
|
|
Webpage
|
PDF Format |
|
|
|
|
02/24/11 |
|
JHP Pharmaceuticals Enters Another Multi-Year Contract Manufacturing Agreement |
|
|
|
Webpage
|
PDF Format |
|
|
|
|
01/27/11 |
|
JHP Pharmaceuticals & Putney Inc. Announce Multi-Year Contract Manufacturing Agreement |
|
|
|
Webpage
|
PDF Format |
|
|
|
|
06/29/10 |
|
JHP Pharmaceuticals Announces Multi-Year Contract Manufacturing Agreement |
|
|
|
Webpage
|
PDF Format |
|
|
|
|
05/10/10 |
|
JHP Pharmaceuticals Announces Successful
Completion of FDA and EMEA GMP Audits |
|
|
|
Webpage
|
PDF Format |
|
|
|
|
09/28/09 |
|
JHP Announces FDA Approval for Dantrium IV, rapidly mixing in 20 seconds
|
|
|
|
Webpage
|
PDF Format |
|
|
|
|
08/20/08 |
|
JHP Pharmaceuticals & SpePharm complete
purchaseof Dantrium® (dantrolene sodium)
|
|
|
|
Webpage
|
PDF Format |
|
|
|
|
07/16/07 |
|
King Pharmaceuticals Completes Sale Of Rochester, Michigan Manufacturing Facility
To JHP Pharmaceuticals |
|
|
|
Webpage
|
PDF Format |
|
|
|
Return To Press & News
»
